Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H32F3N5O6S |
| Molecular Weight | 635.654 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=CC(C)=C1CCS(=O)(=O)N2CCC3(CC2)N=C(NC3=O)C4=CC=C(OC(F)(F)F)C=C4)N5C(=O)NC(=O)C5(C)C
InChI
InChIKey=LDZJFVOUPUFOHX-UHFFFAOYSA-N
InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)
| Molecular Formula | C29H32F3N5O6S |
| Molecular Weight | 635.654 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chugai Pharmaceutical is developing a parathyroid 1 receptor agonist called as PCO371. It is known that parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor. PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism. This drug participated in phase I clinical trial in healthy volunteers. However, Chugai Pharmaceutical has terminated this study. No recent reports of the development of PCO371are available.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:00:59 GMT 2023
by
admin
on
Fri Dec 15 19:00:59 GMT 2023
|
| Record UNII |
TE53TU0WSQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
455914
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000005135
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
PRIMARY | |||
|
1613373-33-3
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
PRIMARY | |||
|
DB14946
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
PRIMARY | |||
|
TE53TU0WSQ
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
PRIMARY | |||
|
76283707
Created by
admin on Fri Dec 15 19:00:59 GMT 2023 , Edited by admin on Fri Dec 15 19:00:59 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers
Purpose: This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in healthy adult males. Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.
|
||
|
ACTIVE MOIETY |
Drug: PCO 371(Primary); Indication: Hypo-parathyroidism; Focus: Adverse reactions, Pharmacokinetics; Sponsor: Chugai Pharmaceutical; Most Recent Events: 19 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov., 26 Jun 2015 New trial record, 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
|
